Shirley Ryan AbilityLab, Chicago, Illinois, United States.
Department of Physical Medicine and Rehabilitation, Northwestern University, Chicago, Illinois, United States.
J Appl Physiol (1985). 2024 Sep 1;137(3):705-717. doi: 10.1152/japplphysiol.00173.2024. Epub 2024 Jul 25.
Progressive functional decline is a key element of cancer-associated cachexia. Major barriers to translating preclinical therapies into the clinic include lack of cancer models that accurately mimic functional decline, which develops over time, and use of nonspecific measures, like grip strength, as surrogates for physical function. In this study, we aimed to extend the survival and longevity of a cancer model, to investigate cachexia-related function at the basic science level. Survival extension studies were performed by testing multiple cell lines, dilutions, and vehicle-types in orthotopic implantation of K-ras; Trp53; Pdx-1-Cre (KPC)-derived cells. One hundred twenty-eight animals in this new model were assessed for cachexia syndrome phenotype using a battery of anatomical, biochemical, and behavioral techniques. We extended the survival of the KPC orthotopic model to 8-9 wk postimplantation using a relatively low 100-cell dose of DT10022 KPC cells ( < 0.001). In this low-dose orthotopic (LO) model, progressive muscle wasting was detected in parallel to systemic inflammation; skeletal muscle atrophy at the fiber level was detected as early as 3 wk postimplantation compared with controls ( < 0.001). Gait speed in LO animals declined as early as 2 wk postimplantation, whereas grip strength change was a late event. Principal component and regression analyses revealed distinct cachectic and noncachectic animal populations, which we leveraged to show that the gait speed decline was specific to cachexia ( < 0.01), whereas grip strength decline was not ( = 0.19). Gait speed represents an accurate surrogate for cachexia-related physical function as opposed to grip strength. Previous studies of cancer-induced cachexia have been confounded by the relatively rapid death of animal subjects. Using a lower dose of cancer cells in combination with a battery of behavioral, structural, histological, and biochemical techniques, we show that gait speed is actually the best indicator of functional decline due to cachexia. Future studies are required to define the underlying physiological basis of these findings.
进行性功能下降是癌症相关恶病质的一个关键因素。将临床前疗法转化为临床应用的主要障碍包括缺乏能够准确模拟随时间推移而发展的功能下降的癌症模型,以及使用握力等非特异性措施作为身体功能的替代物。在这项研究中,我们旨在延长癌症模型的存活时间和寿命,以在基础科学层面研究恶病质相关的功能。通过在 K-ras;Trp53;Pdx-1-Cre (KPC)衍生细胞的原位植入中测试多种细胞系、稀释液和载体类型,进行了延长存活时间的研究。使用一系列解剖学、生物化学和行为技术,对该新型模型中的 128 只动物进行恶病质综合征表型评估。我们使用相对较低的 100 个 DT10022 KPC 细胞剂量(<0.001),将 KPC 原位模型的存活时间延长至植入后 8-9 周。在这种低剂量原位(LO)模型中,在系统性炎症的同时,检测到进行性肌肉消耗;与对照组相比,早在植入后 3 周就检测到骨骼肌在纤维水平上的萎缩(<0.001)。LO 动物的步态速度早在植入后 2 周就开始下降,而握力变化则是一个晚期事件。主成分和回归分析显示出明显的恶病质和非恶病质动物群体,我们利用这些群体表明,步态速度下降是恶病质特有的(<0.01),而握力下降则不是(=0.19)。步态速度是反映与恶病质相关的身体功能的准确替代指标,而不是握力。以前关于癌症引起的恶病质的研究受到动物受试者相对较快死亡的影响。通过使用较低剂量的癌细胞,并结合一系列行为、结构、组织学和生物化学技术,我们表明步态速度实际上是恶病质导致功能下降的最佳指标。需要进一步的研究来定义这些发现的潜在生理基础。